Dividend Contenders List: Top 15

3. Pfizer Inc. (NYSE:PFE)

Dividend Yield as of March 12: 6.69%

Pfizer Inc. (NYSE:PFE) is a New York-based pharmaceutical and biotech company that mainly manufactures, markets, and sells related products worldwide. In recent years, the company has prioritized expanding its footprint in oncology, including a major $43 billion acquisition of Seagen to bolster its cancer treatment portfolio. It anticipates substantial growth in this segment over the next five years, with plans to double its patient base by 2030 and launch at least three blockbuster drugs, each expected to generate over $1 billion in annual sales. The company’s progress in oncology is already evident, with revenue from this segment increasing by 25% in 2024.

Pfizer Inc. (NYSE:PFE) recorded a 12% operational revenue increase from its non-COVID products over the past year, highlighting its focus on strategic execution. The company successfully achieved its $4 billion net cost savings target through an ongoing cost realignment initiative and has now raised its goal to approximately $4.5 billion by the end of 2025. In addition, as part of its Manufacturing Optimization Program, it aims to realize $1.5 billion in net cost savings by 2027, with the first benefits expected in the latter half of 2025. The company remains confident in its ability to restore pre-pandemic operating margins in the coming years.

Pfizer Inc. (NYSE:PFE) currently offers a quarterly dividend of $0.43 per share, having raised it by 2.4% in December 2024. This marked the company’s 15th consecutive year of dividend growth. The stock’s dividend yield on March 12 came in at 6.69%.